Alain Fischer, the government’s “Mr. Vaccine,” recommends that people suffering from serious pathologies “benefit from next Monday’s vaccine,” regardless of age.
“Today, in France and in any country in the world, there are not enough vaccines to vaccinate the entire population. This Wednesday, heard by the deputies of the Committee on Social Affairs in the National Assembly, Professor Alain Fischer warned of the available quantities of anti-Covid serum.
In late November, Pfizer and BioNTech said they were capable of producing 1.3 billion doses in 2021. Modern weighs between 500 million and 1 billion annual doses, it was underlined at the time. France Inter. Too little to vaccinate the entire world population. That is why it is “necessary to determine priorities”, explains the professor of pediatric immunology and a researcher in biology.
“Those who are most endangered should be vaccinated as soon as possible.
Vaccinate the most endangered
In addition to the elderly who live in retirement homes, these are especially patients with pathologies that the medical profession determines that they must benefit from the “extremely high priority of vaccination.”
“These are cancer patients undergoing chemotherapy, patients with chronic renal failure, transplant recipients, people with Down syndrome. That represents several hundred thousand people we believe should benefit from next Monday. Vaccines,” regardless. age, in detail during a video conference with MPs Alain Fischer, president of the Council for the Orientation of the vaccine strategy established by the government.
The schedule is accelerating, but we are waiting for deliveries
Last week, the CEO accelerated the pace of his vaccination strategy by opening it to “health workers over 50 (1.2 million people)”.
“Next Monday, this will apply to people over the age of 75 outside retirement homes, representing 5 million people. Then we will target people who are still at risk, but a little less, like those aged 65 to 74,” always in this logic of establishing priorities in order to vaccinate, first, the most vulnerable.
In total, these priority segments of the population represent a need for 16 million doses of vaccines. “It is certain that we will not have them in January or February, even if I hope that there will be a big boost with the AstraZeneca vaccine,” which has not yet received marketing approval, underlines Professor Alain Fischer.